Research Article
[Retracted] Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World
Table 2
Correlation between patient clinical test data and tumor PD-L1 expression.
| | () | () | () | value |
| | R-interferons (pg/mL) | 1.75 (0.95) | 1.79 (1.48) | 1.32 (0.53) | 0.634 | | CD4 (%) | 33.64 (10.59) | 38.57 (8.73) | 32.81 (16.03) | 0.447 | | CD8 (%) | 20.82 (8.99) | 25.68 (11.40) | 17.19 (7.37) | 0.137 | | NLR (%) | 4.08 (4.11) | 4.42 (3.12) | 4.34 (3.18) | 0.771 | | CRP (mg/L) | 27.62 (39.29) | 26.67 (41.28) | 38.05 (43.80) | 0.188 | | Propagated (g/L) | 39.51 (5.41) | 37.37 (5.36) | 37.52 (4.92) | 0.014 | | LDH (U/L) | 242.82 (218.95) | 201.13 (107.23) | 226.38 (166.00) | 0.254 |
|
|
NLR: ratio of neutrophil count to lymphocyte count; CRP: C-reactive protein; LDH: lactate dehydrogenase.
|
